Collectively, flubendazole suppressed breast cancer by inducing mitochondrial dysfunction through promoting DRP1-mediated mitophagy via upregulating EVA1A, which provides a new mechanism for targeting EVA1A in the treatment of breast cancer [28]. This evidence concerns the gene EVA1A and breast carcinoma.